• news.cision.com/
  • Spago/
  • BioStock: Spago Nanomedical’s CEO: “huge commercial opportunities are unfolding”
English

BioStock: Spago Nanomedical’s CEO: “huge commercial opportunities are unfolding”

Report this content

Last week we saw the USD 2 billion buyout of Fusion Pharmaceuticals by AstraZeneca to accelerate the development of next-generation radioconjugates to treat cancer. The deal showcases rising interest in the field of radiopharmaceuticals. BioStock got in touch with Mats Hansen, CEO of Swedish radiopharma company Spago Nanomedical to get his take on the deal and where Spago is in its development of lead programme Tumorad.

Read the article at biostock.se:

Spago Nanomedical’s CEO: “huge commercial opportunities are unfolding” - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Subscribe

Documents & Links

Quick facts

BioStock: Spago Nanomedical’s CEO: “huge commercial opportunities are unfolding”
Tweet this